Psychological Intervention for Improving Cognitive Function in Cancer Survivors: A Literature Review and Randomized Controlled Trial by Summer King & Heather Joy Green
ORIGINAL RESEARCH ARTICLE
published: 25 March 2015
doi: 10.3389/fonc.2015.00072
Psychological intervention for improving cognitive
function in cancer survivors: a literature review and
randomized controlled trial
Summer King and Heather Joy Green*
Menzies Health Institute Queensland and School of Applied Psychology, Griffith University, Gold Coast, QLD, Australia
Edited by:
Haryana Mary Dhillon, The University
of Sydney, Australia
Reviewed by:
Marianne S. Elston, Waikato Hospital,
New Zealand
David D. Eisenstat, University of
Alberta, Canada
*Correspondence:
Heather Joy Green, School of Applied
Psychology, Parklands Drive, Gold
Coast Campus, Griffith University,
Southport, QLD 4222, Australia
e-mail: h.green@griffith.edu.au
Although the impact of cancer and associated treatments on cognitive functioning is
becoming an increasingly recognized problem, there are few published studies that
have investigated psychological interventions to address this issue. A waitlist random-
ized controlled trial methodology was used to assess the efficacy of a group cognitive
rehabilitation intervention (“ReCog”) that successfully targeted cancer-related cognitive
decline in previously published pilot research. Participants were 29 cancer survivors
who were randomly allocated to either the intervention group or a waitlist group who
received the intervention at a later date, and 16 demographically matched community
volunteers with no history of cancer (trial registration ACTRN12615000009516, available
at http://www.ANZCTR.org.au/ACTRN12615000009516.aspx). The study was the first to
include an adapted version of the Traumatic Brain Injury Self-Efficacy Scale to assess
cognitive self-efficacy (CSE) in people who have experienced cancer. Results revealed par-
ticipating in the intervention was associated with significantly faster performance on one
objective cognitive task that measures processing speed and visual scanning. Significantly
larger improvements for the intervention group were also found on measures of perceived
cognitive impairments and CSE. There was some evidence to support the roles of CSE
and illness perceptions as potential mechanisms of change for the intervention. Overall,
the study provided additional evidence of feasibility and efficacy of group psychological
intervention for targeting cancer-related cognitive decline.
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INTRODUCTION
Research supports a relationship between cancer and associated
treatment and subsequent cognitive impairment in some cancer
survivors (1–3). Reported changes in areas like memory, attention,
executive function, and processing speed have been linked to type
of cancer and advancement of the disease (4), treatments (5), as
well as other issues like increased stress and fatigue (6). As cogni-
tive impairment has the potential to impact quality of life (QoL),
relationships, and adjustment to occupational functioning after
cancer (7), it is an important survivorship issue.
Although the impact of cancer and associated treatments on
cognitive functioning is increasingly recognized, relatively few
published studies have investigated psychological intervention
programs to address this issue in survivors of adult-onset cancers.
The theoretical basis for such interventions and results of previ-
ous studies will be discussed before describing new randomized
controlled trial (RCT) findings.
BACKGROUND
CANCER AND COGNITION
Reviews assessing the impact of cancer treatments on cogni-
tion, in the absence of known primary or secondary tumors in
the central nervous system (CNS), have indicated cognitive dys-
function frequencies ranging from 13 to 75% (8–10). A recent
meta-analysis that examined 13 studies including a range of cancer
types and cognitive domains found executive function to be most
affected by chemotherapy and found evidence for impairment in
language and memory (11). Seventeen studies met inclusion cri-
teria for another meta-analysis and findings indicated significant
cognitive deficits to be limited to verbal and visuospatial abili-
ties (12). Despite variability in these domains, the meta-analyses
have demonstrated a consistent relationship between cancer and
cognitive impairment. Dysfunction following treatment is often
considered an acute issue that should subside within months after
treatment (13) and some research has indicated no long-term dif-
ferences in cognitive function between people with and without
a history of cancer (14). However, longitudinal research has also
shown that cognitive complaints following treatment may endure
for up to 10 years (15). Several studies have highlighted the impact
of type of cancer and treatments including influence of treatment
received (16–19). It is therefore suggested that a range of fac-
tors may contribute to the variability in prevalence of cognitive
dysfunction after cancer.
Objective and subjective cognitive function
Cognitive dysfunction is measured using both objective and
subjective forms of assessment. Objective measures often pro-
vide information about specific areas of cognition (e.g., working
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memory) allowing for comparison of different domains. Preva-
lence rates of dysfunction are primarily based on objective mea-
sures, but subjective cognitive impairment is reportedly more
prevalent in cancer survivors (9). Subjective measures assess self-
perceptions of cognition including cognitive functioning in a
person’s daily life, and involve self-report assessments such as ques-
tionnaires (9). One large-scale study assessed 1933 breast cancer
survivors, compared to 500 healthy controls, on a range of sub-
jective measures of cognition and found statistically significant
differences between groups (9% of survivors reported subjective
cognition in a problematic range vs. 2.8% for controls) (20).
The association between objective and subjective cognitive
impairment in people with cancer is inconsistent, with some stud-
ies finding a positive association but a higher number of studies
finding no relation between these different forms of measure-
ment (8, 9). An explanation for the discrepancy between objective
and subjective measures of cognitive function is that subjective
impairment is often more an indicator of psychological distress
than a measurement of cognition (8, 21), and several studies have
indicated a relationship between perceived cognition and psycho-
logical factors like mood and distress. It is therefore suggested
that subjective and objective measures of cognition should be
treated as separate assessments and that those who self-report
cognitive concerns should also be screened for other psychological
concerns (17).
Other proposed issues include the potential poor ability of
objective measures to assess the subtle cognitive changes that may
occur as a result of cancer treatment (22) and the need for a more
comprehensive evaluation of mood so the influence of psycholog-
ical factors can be accounted completely. In light of the variable
evidence regarding cancer-related cognitive decline and complex
relationships impacting cognition (e.g., objective and subjective
function, psychosocial factors), it is helpful to consider concep-
tual models designed to assist with interpretation of the research
findings.
Explanatory models
Models have been proposed in order to summarize the relation-
ships among physiological and psychological factors associated
with cancer and cognitive impairment (23–25). Hess and col-
leagues included 70 articles in a systematic review, and developed
a conceptual model of pathways by which cancer treatments may
lead to changes in cognitive functioning (24). Their model incor-
porates antecedents; mediating factors and associated toxicities;
moderators; and consequences for treatment-related cognitive
dysfunction. The model illustrates that multiple factors impact
on subjective/objective cognitive function (grouped together),
and consequently on QoL and functional ability. The model also
accounts for moderating factors which have been shown to influ-
ence the relationship between cancer and cognition (24). When
considering how specific cancer types (termed an “antecedent” in
this model) may be associated with changes in cognitive function,
one issue of note is that various adult-onset cancers have differ-
ent rates of CNS metastases. The frequency of metastases may be
underreported because specific investigations for such metastases
may not occur unless symptoms of CNS dysfunction are evident.
Another point of note is that the model lists varied toxicities that
potentially link some cancer treatments to cognitive changes for
some patients, including anemia, cytokines, hormonal status, and
vascular injury, as well as direct neurotoxicity. Therefore, the evi-
dence does not support one specific, universal mechanism for all
cancer-related cognitive dysfunction.
A model by a different research group proposed predictors of
both subjective and objective cognitive function in people with
cancer (23). The model suggests cancer treatments, emotional
health, and physical health to be predictors of objective cognitive
impairment and that emotional health and objective impairment
may predict subjective cognitive impairment. These authors noted
that, in many instances, subjective measures of cognition are more
strongly related to psychosocial factors such as coping, emotions,
and personal interpretations of a situation (termed “appraisal”),
than to objective cognitive function. Furthermore, their model
suggests psychosocial elements including appraisal and coping
can impact the level of emotional distress and consequently cor-
relate with physical health. It is proposed that the model may
inform interventions by incorporating assessment of individual
vulnerabilities and current difficulties, assisting patient educa-
tion regarding current and prospective cognitive function, and
identifying potential areas for remediation (23).
Vearncombe and Pachana reviewed 22 studies to evaluate the
impact of treatments, health, and psychological factors on cog-
nition for women with breast cancer (26). They proposed that
indirect factors, including psychological well-being, may influence
cognitive performance and found a major gap in the literature
in terms of study of the impact of these indirect factors on
cognition after cancer treatment. Their research highlighted the
potential contribution of psychological variables to cognitive per-
formance for cancer survivors, including the potential to intervene
with psychological approaches even when biological causes may
contribute.
PSYCHOSOCIAL VARIABLES
Quality of life
A psychological variable that has been researched in terms of its
relationship to cancer and cognitive function is QoL. QoL has
been described as subjective perception of how well a person func-
tions across areas of their life and is domain-specific encompassing
the interactions of psychological, physical, social, and spiritual
well-being (27). Areas of QoL impacted by cancer are commonly
reported to include areas like physical, sexual, role, and social func-
tioning (28). Meta-analyses in this area have even supported use
of QoL as a prognostic indicator of survival in some people with
cancer (29, 30).
A systematic review of 28 studies showed worse outcomes on
QoL are reported significantly more frequently by women with
breast cancer than community controls (31). QoL impacted by
breast cancer was related to reduced physical functioning, pre-
mature menopause, and the impact of psychosocial outcomes as
a result of diagnosis and treatment (e.g., depression). Another
review examining the long-term impact of cancer on QoL indi-
cated that survivors (at least 5 years post-treatment) reported
good overall QoL but reported issues with specific areas of QoL
like sexual functioning (32). Predictors of better QoL included
fewer current medical issues, better social support, and higher
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income; chemotherapy treatment was a predictor of worse scores
on measures of QoL.
Although limited, there is some research into the impact of
cancer-related cognitive decline on QoL. Research has shown per-
ceived cognitive impairment after cancer treatment to be linked
to reduced QoL, daily functioning, reduced work efficiency, and
negative reactions from others (7). One study of health-related
QoL in 76 people with cancer found individuals with higher sub-
jective cognitive deficits reported worse health-related QoL (33).
A qualitative study of men randomized to androgen-suppressing
medication for prostate cancer found that decreased cognitive
function was the most frequent change in behavior or symp-
toms that participants attributed to their medication (34). Overall,
existing research indicates that there is a need for more research
investigating the relationship between cognitive functioning and
QoL in cancer survivors.
Psychological distress
Research supports that diagnosis of cancer and treatment may
lead to increases in mental health issues including depression and
anxiety (35–37). A meta-analysis of 58 studies that investigated
psychological outcomes related to cancer diagnosis found varied
results in terms of significantly less psychological problems when
compared to a psychiatric population, but significantly higher
levels of depression than a “normal” population (38). Among a
sample of 1083 people with breast cancer, at least 40% had one
psychological diagnosis, 38% exhibited moderate-high rates of
anxiety, 22% reported moderate-high depression, 12% exhibited
post-traumatic stress disorder, and 7.8% met diagnostic criteria for
all three diagnoses (39). Increased rates of comorbid depression
have also been correlated with the advancement of the disease (40).
It has been reported that psychological disorders like depres-
sion and anxiety may impact cognitive function in the general
population and a range of clinical populations (41, 42). Depres-
sion has been particularly linked to deficits in attention and a large
study that examined depression, anxiety, and cognitive function in
an elderly population found a significant and almost linear rela-
tionship between depression and objective measures of impaired
cognitive function (41). Some research has not found a correlation
between psychological distress and objective cognitive function in
people with cancer (13, 43, 44). However, a number of studies
have shown a relationship between mental health and subjective
cognitive impairment in this population (13, 18). These findings
indicate that subjective complaints regarding cognitive impair-
ment may be more revealing of emotional distress than objective
cognitive impairment (18), and also suggest there may be other
psychosocial variables that impact psychological well-being in this
population.
Fatigue
Survivors of cancer often report persistent fatigue and it has
been found to affect individuals irrespective of type of cancer or
treatment received (45, 46). Cancer-related fatigue has been asso-
ciated with QoL (47) and psychosocial well-being (35). A system-
atic review including 44 studies demonstrated consistently more
fatigue in cancer groups than the general population with preva-
lence ranging between 39 and 90% (48). Research also suggests
up to a third of people treated with radiation or chemotherapy
continued to experience fatigue 5–10 years after treatment was
completed (49, 50). Cancer-related fatigue may also be associated
with financial burden as it can impair an individual’s ability to
work and perform activities of daily living (51).
The relationship between fatigue and cognitive functioning is
well established in a range of clinical populations including mul-
tiple sclerosis (52) and chronic fatigue syndrome (53), but results
have been mixed when investigating populations with cancer.
One study found no differences between severely fatigued cancer
survivors, non-severely fatigued cancer survivors, and the con-
trol group on objective neuropsychological assessments; but the
severely fatigued group scored significantly worse on self-report
assessments of cognitive functioning (54). These results suggested
that cancer-related fatigue may be associated with subjective but
not objective cognitive functioning. This is supported by other
studies, which have failed to find a relationship between fatigue
and objective cognitive dysfunction in cancer survivors (55, 56).
Benefit finding
Benefit finding refers to the potential for individuals who have
experienced cancer or other potentially traumatic events to view
aspects or outcomes of their experience as positive or beneficial
(57). Positive experiences post-diagnosis for cancer as reported
by some people may include increased sense of spirituality and
purpose, improved relationships, and increased skills (58).
A meta-analysis of 87 studies investigating benefit finding in
populations with cancer found the construct was related to mea-
sures of positive well-being and less depression but was not related
to measures of anxiety or global distress (59). It was suggested from
this research that benefit finding may be important to consider
when researching survivorship issues as it appears to represent
positive outcomes from illness as opposed to “a mere lack of
distress” (59).
Cognitive self-efficacy
The relationship between confidence in ability to perform cog-
nitive tasks and objective measures of cognitive performance
is a robust finding in the literature (60, 61). Cognitive self-
efficacy (CSE) refers to an individual’s confidence and/or per-
ceptions regarding the effectiveness of their cognitive functioning
in expected situations (62). An individual with low CSE may
avoid tasks they believe to exceed their abilities, for example, they
may not feel that they can solve problems related to their cogni-
tive complaints. In contrast, another person with high CSE may
attempt more challenging tasks, viewing them as goals rather than
threats (63).
Research suggests that among individuals with physical disease
or disablement, functional disability is more strongly predicted by
perceived self-efficacy than by the level of impairment or dura-
tion of illness (64, 65). Specific to cognitive dysfunction, studies
have found CSE and cognitive complaints to be more closely
related than CSE and cognitive capacity (66–68). Measures of self-
efficacy have also been shown to predict cognitive performance
independently of the individual’s level of skill (69, 70).
Several studies have measured aspects of CSE across cognitive
training programs (64, 71). Results have generally found that as
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CSE increases, cognitive performance improves, and where self-
efficacy has not increased, there have also not been substantial
gains in objective performance (71). The theory that CSE may
mediate the degree of improvement during cognitive training
programs, such that an increase in CSE facilitates a more posi-
tive outcome, has also been suggested (64). Further research into
the role of CSE in cognitive rehabilitation programs is therefore
warranted as it “may have considerable heuristic and explanatory
value for understanding the effective ingredients of interventions”
(64) (p. 949).
Illness perceptions
Illness perception is a construct encompassing an individual’s
appraisals and beliefs about their illness (72). A self-regulation
framework posits that an individual’s perceptions of their illness
lead to their choices of coping strategies for dealing with an ill-
ness (73). A meta-analytic review of 45 studies found people
who perceive their illness as highly symptomatic use avoidance
coping strategies in contrast to people who view their illness
as curable/controllable and show more positive social function-
ing, improved mental health, and reduced distress and disease
states (74).
Preliminary evidence from one psychological intervention
study for cognitive impairment in cancer survivors showed a
significant improvement for intervention participants on one
subdomain of illness perceptions (75). This was “illness coher-
ence” regarding cognitive problems, which refers to an individual’s
beliefs about how well they understand the health problem. It
has been suggested that if successfully targeted by interventions,
improvement in illness perceptions would likely be related to
improvement in a range of illness and psychosocial outcomes (76).
Thus, the illness perceptions construct shows promise as a media-
tor of outcomes in psychosocial intervention studies but there has
been little research to test this in the context of cognitive concerns
for cancer survivors.
INTERVENTIONS FOR CANCER-RELATED COGNITIVE DYSFUNCTION
Pharmacological interventions
A number of pharmacological agents have been trialed for their
use in addressing cognitive impairment after cancer. Reviews
have identified erythropoietin, methylphenidate, and modafinil
as pharmacological agents that may reduce cognitive impairment
following treatment (25, 77). Despite these promising results, there
are studies which have not shown any improvement in cognitive
performance with medications (78) and it is noted that pharma-
cological treatments often have side-effects (79). For example,
the presence of erythropoietin receptors in many cancers may
raise concerns about potential increased risk of tumor growth
or recurrence with use of erythropoietin to address these issues.
Therefore, consideration of non-pharmacological, psychosocial
interventions is important.
Psychosocial interventions
Published research has only relatively recently reported psycho-
logical interventions for cognitive dysfunction following treatment
for adult-onset non-CNS malignancies. Many of these studies were
published after the current study began in 2012. Some studies
have focused on cognitive training, such as computerized exer-
cises designed to strengthen relevant cognitive processes. Other
studies have taken a broader cognitive rehabilitation approach,
which may include cognitive skills training but also incorporates
program elements such as psychoeducation, compensatory strat-
egy training, and between session homework tasks (80). Cognitive
rehabilitation usually incorporates cognitive behavioral therapy
(CBT) principles. Some studies have used individually delivered
interventions, whereas others have taken place in a group format.
Please see Table 1 for information on psychological interventions
addressing cancer-related cognitive impairment.
The studies described in Table 1 show support for both group
and individual psychosocial interventions for this clinical issue.
In the limited research to date, no specific advantage has been
shown for interventions with a broader cognitive rehabilitation
approach compared to more focused cognitive training. Research
has supported beneficial effects of psychological interventions for
cancer-related cognitive impairment in studies of mixed tumor
types (75, 81, 84, 87) as well as in studies limited to women treated
for breast cancer (82, 83, 85, 86, 88, 89).
However, there are limitations in the research to date. Only
one of the studies described in Table 1 included a matched atten-
tion control condition, and did demonstrate additional beneficial
intervention effects in comparison to the health information arm
(84). However, this research context was not specific to cancer
survivors (84), so it is unclear whether an attention control that
more specifically focuses on the concerns of cancer survivors
might have additional benefits. The one study that did not find
any additional benefit of psychological interventions designed to
improve cognitive performance in comparison to treatment as
usual was conducted in conjunction with inpatient cancer reha-
bilitation received by all participants, so it could be that the overall
rehabilitation program acted as an attention control (83).
Psychological intervention studies to date have had relatively
small sample sizes, and in some instances the findings associated
with the intervention have represented only a small proportion
of the statistical comparisons within the studies. Measures have
varied, so it is difficult to make direct comparisons between stud-
ies. The majority of studies either investigating or intervening
for cognitive impairment in cancer survivors with no known
CNS tumors have been limited to samples with female breast
cancer survivors and people treated with chemotherapy, making
generalization of results to males and other cancer types diffi-
cult. Nevertheless, cancer-related cognitive impairment has been
found in both sexes, in association with a range of cancer types
and treatments, and clinically significant responses to cognitive
rehabilitation have been found following colorectal, prostate, and
testicular cancer as well as breast cancer (75). Moderators and
mediators of intervention effectiveness are yet to be identified.
OVERVIEW OF CURRENT STUDY
The present study aimed to test the efficacy and potential psycho-
logical mechanisms of a group intervention (ReCog) for cancer
survivors targeting cognitive decline. Design elements intended to
address gaps in the literature included incorporating a range of
cancer types, using RCT design, and testing relevant psychological
outcomes including potential explanatory variables.
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Table 1 | Psychological intervention studies addressing cognitive impairment in cancer survivors.
Reference Design Participants Intervention Results
(81) RCT
(intervention
vs. waitlist)
78 adults aged
65+ years with a
history of chronic
disease (n=11
history of cancer)
Cognitive Behavioral Model of Everyday
Memory (CBMEM): efficacy and awareness
building, health promotion, strategy use, and
relaxation. Group intervention, 8 sessions of
1.25 h each, over 4 weeks
Cancer survivors in intervention group
improved in short-term memory on the
Rivermead Behavioral Memory Test,
memory self-efficacy, and metamemory.
(Note: not planned as a cancer substudy)
(82) Single-arm
study
29 women at
least 3 years post-
chemotherapy for
breast cancer
Memory and Attention Adaptation Training
(MAAT): education, self-awareness training,
self-regulation, compensatory strategies.
Individual therapy, 4 sessions of 30–50 min
each, once per month, plus up to 3 phone
calls and participant workbook
Significant improvements in
neuropsychological test performance,
self-reported cognitive function, and QoL
(83) Partially
Randomized
Controlled Trial
(two
interventions
vs. treatment-
as-usual)
96 women post-
chemotherapy for
stage I or II
breast cancer,
undergoing
inpatient cancer
rehabilitation
Neuropsychological Training Group: small
group functional training and compensatory
strategies for memory and attention in
everyday situations. Computer intervention:
individual therapist support for using
software addressing memory/attention. Both
groups attended 4 1-h sessions per week
during their stay in hospital (3–5 weeks)
Improvements across most
neuropsychological measures for all
participant groups (i.e., no effects were
specific to the interventions)
(84) RCT
(intervention
vs. active
control)
267 adults aged
65+ years; 22
cancer survivors:
14 intervention
group, 8 control
group
CBMEM (see above) compared to health
information control condition
Cancer survivors in CBMEM declined less
in visual memory performance over
14 months and improved more than control
group on subjective memory measures.
(Note: not planned as a cancer substudy)
(85) RCT (two
interventions
vs. waitlist)
88 breast cancer
survivors
Memory training: group memory exercises
and skills practice. Processing speed:
computerized training using increasingly
difficult processing tasks. Both interventions
used 10 1-h training sessions in small groups
over 6–8 weeks
Both intervention groups improved
neuropsychological test performance more
than waitlist group, but processing speed
training showed earlier benefits and
generalized to memory performance
whereas memory training not associated
with changed processing speed. Both
showed improvements in subjective
cognition, QoL, and distress
(86) RCT
(intervention
vs. waitlist)
40 women
18-months
post-treatment
for breast cancer
MAAT (see above) Intervention group improved significantly
more than waitlist participants on verbal
memory (California Verbal Learning Test)
and one QoL subscale (spiritual well-being)
(75) Non-
Randomized
Controlled Trial
(intervention
vs. waitlist vs.
community)
55 participants.
32 cancer
survivors
>4 months
post-treatments;
23 community
comparison
Responding to Cognitive Concerns (ReCog):
education, compensatory and enhancement
strategies for memory, attention, emotional
adjustment, sleep, and fatigue. Group
sessions lasting 2 h held weekly for 4 weeks,
participant workbook/homework
Significantly greater improvement on
overall cognitive function, immediate
memory, visuospatial/constructional, and
delayed memory measures for intervention
group. Reduction in subjective cognitive
impairment and distress for intervention
group
(87) RCT
(intervention
vs. waitlist)
28 adult cancer
survivors
>6 months
post-treatment
Workshops addressing memory aids,
memory skills, and mindfulness meditation.
Group sessions lasting 1 h held weekly for
7 weeks
Intervention group improved significantly
more than waitlist group on digit span and
subjective cognition
(Continued)
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Table 1 | Continued
Reference Design Participants Intervention Results
(88) Single-arm
study
27 women
1.5–5 years
post-treatments
for breast cancer.
n=8 for EEG
substudy
Cognitive rehabilitation, targeting attention,
executive and memory challenges. Group
sessions lasting 2 h held weekly for 5 weeks,
participant workbook/homework
Significant improvements on Symbol Digit,
Stroop reaction time, Trails A time, and
subjective cognition. Increase in EEG alpha
power was associated with improved
subjective cognition at 2-month follow-up
(89) RCT
(intervention
vs. waitlist)
41 breast cancer
survivors
Online, computerized training program
targeting executive function. Individual,
home-based sessions lasting 20–30 min
conducted 4 times per week for 12 weeks
Adherence was high. Intervention group
improved significantly more on Wisconsin
Card Sort Test, letter fluency, and symbol
search, as well as some aspects of
subjective executive function
It was hypothesized that there would be significantly greater
improvements on objective cognitive function for participants in
an intervention group than for participants in waitlist and com-
munity groups (Hypothesis 1). Similarly, it was predicted that
the intervention group would show significantly greater improve-
ments than other participants in subjective cognitive function
(Hypothesis 2); in psychosocial measures including QoL, fatigue,
distress, and benefit finding (Hypothesis 3); and in potential psy-
chological explanatory variables of CSE and illness perceptions
(Hypothesis 4). It was predicted that improvements in CSE and
illness perception would be significantly associated with greater
improvements in objective and subjective cognitive function
(Hypothesis 5).
MATERIALS AND METHODS
PARTICIPANTS
There were 16 intervention participants (aged 37–65, M = 50.4,
SD= 8.8 years), 13 waitlist control participants (aged 40–72,
M = 51.8, SD= 9.4), and 16 community comparison participants
(aged 27–77 years, M= 52.9, SD= 4.3). Intervention and waitlist
participants had experienced adult-onset cancer, excluding can-
cer affecting the CNS, and had completed major treatments for
cancer at least 6 months prior. A further requirement was that
these participants report subjective cognitive impairment on the
EORTC Cognitive Functioning Subscale prior to the intervention
(score of less than 100). Inclusion criteria for the community com-
parison group stipulated participants to be adults (over 18 years)
who had never been diagnosed with cancer. RCT participants were
recruited in 2012 and 2013 via Griffith University email and can-
cer support groups. Community comparison participants were
recruited in 2009 and 2010 via contacts of the research assistants
for a parallel psychometric study of 36 participants, from which
16 were selected to match the intervention participants for sex,
age, and years of education. Statistical analyses revealed no sig-
nificant differences among groups on demographic variables at
baseline.
Cancer survivors were randomly allocated to intervention
(n= 16) and waitlist control groups (n= 14). Randomization was
conducted by a colleague unconnected to the research project who
used a random number table to generate the allocation sequence
and prepared numbered opaque envelopes that were opened at the
end of the initial assessment session. One participant who was ran-
domly allocated to the waitlist group was excluded from analyses
due to a pre-existing neurological condition.
MEASURES
Primary outcomes: cognitive measures
The Repeatable Battery for Assessment of Neuropsychological
Status (RBANS) (90) is a 30-min battery that assesses objective
cognitive function. Good validity and reliability of the RBANS
have been reported (91, 92), with strong internal consistency in
clinical populations, e.g., total score Cronbach’s alpha of 0.84 in
people with traumatic brain injury (92).
The Trail Making Test (TMT) assesses attention, spatial orga-
nization, visual scanning, executive function, speed of processing,
and mental flexibility (93). The TMT has exhibited good valid-
ity and reliability and is particularly sensitive to neurological
impairment (93, 94).
The Functional Assessment of Cancer Therapy – Cognitive
Scale Version 3 (FACT-Cog 3) (95) was designed for people with
cancer and is used to measure areas of subjective cognitive func-
tion including perceived impairment, perceived ability, comments
from other people regarding cognition, and QoL. Research has
found high internal consistency for subscale scores on Version 2 of
the scale, which has similar items and subscales to Version 3 (96).
The Brief Assessment of Prospective Memory (BAPM) (97)
was used to assess subjective prospective memory. There are two
subscales comprising the BAPM: the basic activities of daily liv-
ing (BADL, e.g., forgetting to lock the door when leaving home)
and instrumental activities of daily living (IADL, e.g., leaving the
iron on). The BAPM has shown Cronbach’s alpha of 0.74–0.76 for
subscales (97).
Secondary outcomes: psychosocial measures
The European Organization for Research and Treatment of Can-
cer Core Quality of Life Questionnaire (EORTC-QLQ-C30) (98)
is designed to assess aspects of QoL relevant to cancer. Recent
research demonstrates high internal reliability with Cronbach’s
alpha above 0.80 for the functional scales (99), and reliability and
consistency across cultures (100).
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The Kessler Psychological Distress Scale (K10) (101) is designed
to measure psychological distress including depression and
anxiety. Research has indicated high levels of internal consistency,
concurrent validity, and discriminant validity for the K10 (101).
The Benefit Finding Scale (102) assesses perceptions of posi-
tive contributions to life due to cancer diagnosis and treatment.
Cronbach’s alpha of 0.90 or higher has been reported (103).
The current study adapted the Traumatic Brain Injury Self-
Efficacy Scale (104) to assess CSE. Items ask participants to rate
confidence that they can manage their symptoms related to their
TBI or cognitive disorder. This wording was adapted slightly so
that it referred to “symptoms related to your cancer-related cog-
nitive difficulties.” The original scale was piloted with 21 military
veterans experiencing mild cognitive disorder and with a history
of TBI (104). Reliability of the adapted scale was assessed to be
good for the current sample (Cronbach’s alpha= 0.91–0.95).
The Brief Illness Perception Questionnaire (B-IPQ) (72) was
designed to assess cognitive and emotional representations of
illness. Cancer survivor participants completed this measure in
relation to “your cognitive difficulties” and community partici-
pants were asked to respond by imagining what they thought it
would be like to experience “cognitive difficulties, such as a prob-
lem with your attention or memory.” Questions address issues like
personal concern about cognitive difficulties, beliefs about benefit
of treatment, and control over their difficulties. Previous research
showed good test–retest reliability over 3- and 6-week time periods
(r = 0.42–0.75) and good concurrent validity (72).
A participant satisfaction survey was completed by participants
in the intervention group after the final group session (75).
INTERVENTION
The current study implemented an intervention that was previ-
ously developed and evaluated in an initial feasibility study (75).
The intervention was titled “Responding to Cognitive Concerns
(ReCog): a four session cognitive rehabilitation program for adults
recovering from cancer.” The program comprised four topics: (1)
aging, health, cancer, and cognitive function; (2) memory; (3)
attention; and (4) fatigue,emotions,and cognition. The program is
manualized for clinicians (105) and participants (106). The inter-
vention included four 2-h sessions held weekly across 4 weeks and
participants were required to complete homework between ses-
sions. Each session included psychoeducation, group discussion,
and skill development and application (75). The three interven-
tion groups of three to eight participants were co-facilitated by
two psychologists, offered at no cost, conducted at university
campuses, and also offered to all waitlist control participants
once they had completed assessments. Waitlist participants were
able to seek any medical or health services they required during
the study, with no restrictions apart from not being eligible to
undertake the ReCog intervention until they had completed data
collection.
PROCEDURE
The study was approved by the Griffith University Human
Research Ethics Committee (PSY/16/12/HREC) and met the
required regulatory standards for research with human partici-
pants. The trial was registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12615000009516). Data were col-
lected at Griffith University in South-East Queensland, Australia.
Baseline assessments took place within 2 weeks before the inter-
vention commenced. At Time 1, participants completed objective
measures of cognitive function followed by questionnaires, and
group assignment was then revealed. At Time 2 and Time 3 assess-
ments (within 2 weeks of intervention completion and at 3 months
post-intervention), all participants were asked to complete the
assessment battery.
Time 1 assessments were conducted by the first author, and
Time 2 and 3 assessments were conducted by independent psy-
chologists who were blind to the participant’s group membership.
Participants in the community comparison group completed the
same assessment battery as participants in the other two groups
(excluding three of the questionnaires), across Times 1 and 2 only.
STATISTICAL ANALYSES
Subscales and total scores for questionnaires were calculated using
pro-rating methods suggested in the EORTC-QLQ-C30 scoring
manual (107). The algorithms computed for each measure calcu-
lated the mean of all completed items where there was a minimum
of 50% response and then substituted this value for the missing
items.
Analysis of data from the RCT participants was conducted
using 2 (Group)× 3 (Time) mixed factorial analyses of variance
(ANOVA). Analysis of all three groups was conducted using 3
(Group)× 2 (Time) ANOVA. Simple effects analysis was used to
follow up significant interactions. Planned contrasts comparing
the intervention group to the waitlist group and to the commu-
nity comparison group were used to follow up any effects of group.
Effect sizes were calculated following guidelines for pre-test–post-
test control group designs, using the Cohen’s d approach (108).
A sample size of 40 RCT participants was planned, based on
a priori power analysis showing that this would yield more than
80% power for detecting Group×Time interactions for primary
outcome measures, at α= 0.05 and with effect size estimated as
Cohen’s d= 0.5–1.0 from previous research. Personnel and finan-
cial resources allowed 30 participants to be recruited for the RCT
during the time available for the study, which was computed to
provide adequate power based on previous estimates of effect.
Intention-to-treat (ITT) analysis was conducted in the case of
two participants who missed two assessments (109). There was
no difference to the pattern of results when these two cases were
included or excluded, and so these cases were excluded from
relevant longitudinal analyses to provide “completer” analyses.
Clinical significance and reliable change scores were calculated
with the clinical cut-off score being 1 SD below the Time 1 mean
of the community comparison group. For measures where there
was no data for this group (e.g., CSE), the Time 1 mean and SD
for the waitlist group was used. The Reliable Change Index (RCI)
was calculated using a formula, which includes a correction for
practice effects as a result of test–retest designs (110). On the
basis of clinical significance and reliable change scores, individ-
uals were classified into change categories (recovered, improved,
unchanged, deteriorated, or false positive) and the frequencies
of the change categories were compared between groups using
Fisher’s Exact Test.
www.frontiersin.org March 2015 | Volume 5 | Article 72 | 7
King and Green Group intervention for cognitive function
To investigate potential mechanisms of change, change scores
between Time 1 and Time 2 were calculated for CSE and illness
perceptions. To be candidate mechanisms of effect, these variables
would need to be associated with receiving the intervention and to
show changes that preceded change on outcome measures (111).
Therefore, the change scores for CSE and illness perceptions were
investigated for correlations with group assignment (intervention
or waitlist) and with objective and subjective cognitive changes
between Time 1 and Time 3.
RESULTS
DATA SCREENING AND PRELIMINARY ANALYSES
One intervention participant withdrew after Time 1 assessment
and one waitlist participant did not complete Time 2 question-
naires or any Time 3 assessment. Missing data for specific ques-
tionnaires at single time points reduced the sample size slightly for
analyses of Benefit Finding (by three intervention participants and
two waitlist participants), K10 (one intervention and one waitlist
participant), and FACT-Cog 3 (one waitlist and one community
participant). There were no other missing data.
Several variables were skewed. Because transformations to cor-
rect skewness did not change the pattern of results, the untrans-
formed data were retained for analyses. Inclusion or exclusion of
outliers did not change results, and therefore outliers were retained
for analyses. No corrections were needed for heterogeneity of
variance (112).
Across the intervention group programs, 10 of the 15 partici-
pants attended all four group sessions (67%), and 5 participants
attended three group sessions (33%). Five waitlist participants
attended the intervention offered after completing their third
assessment (39%).
PARTICIPANT CHARACTERISTICS
Participant demographic and medical data at Time 1 are shown in
Table 2. There were no statistically significant differences among
the groups in any of the demographic or medical variables. The
two cancer groups also did not differ significantly from each other
at Time 1 on any of the cognitive or psychosocial measures.
COGNITIVE RESULTS
Objective cognitive function
Descriptive statistics and RCT effect sizes for objective and sub-
jective cognitive measures are shown in Table 3. At Time 1, only
one cognitive measure, the RBANS Visuospatial/Constructional
measure, showed a significant difference among the groups, F (2,
41)= 4.45, p= 0.018. This effect occurred because the interven-
tion group scored significantly worse than the community group,
p= 0.031, and the waitlist group showed a trend toward worse
performance than the community group, p= 0.063.
For ANOVAs comparing the two cancer groups across three
time points, there were no main effects of group on objec-
tive cognitive function. There was a main effect of time on
all objective cognitive measures except for TMT B, indicating
significant improvements over time. For TMT B, the time effect
approached significance, F (2, 50)= 2.95, p= 0.062, η2p = 0.11.
There was a significant Group×Time interaction for TMT A,
Table 2 | Participant characteristics.
Variable Intervention (n=16) Waitlist (n=13) Community (n=16)
M (SD) Range M (SD) Range M (SD) Range
Age (years) 50.4 (8.8) 37–65 51.8 (9.4) 40–72 52.9 (17.0) 27–77
Education (years) 15.8 (4.0) 11–26 13.8 (3.5) 9–20 13.9 (3.8) 10–20
Time since cancer diagnosis (months) 46.1 (22.8) 15–87 69.2 (56.5) 14–189 – –
Time since finished cancer treatment (months) 37.1 (24.6) 6–84 46.5 (46.1) 6–137 – –
% % %
Living with partner 68.8 84.6 75.0
Female 93.8 100.0 93.8
Born in Australia 62.5 76.9 56.3
Neurological history 0.0 6.3 0.0
Cancer type
Breast 75.0 76.9 –
Hematological 6.3 15.4 –
Colorectal 6.3 7.7 –
Prostate 6.3 – –
Ovarian 6.3 – –
Previous treatment
Chemotherapy 81.3 100.0 –
Radiotherapy 81.3 84.6 –
Surgery 87.5 84.6 –
Other 81.3 69.2 –
Hormone treatment (current) 68.8 69.2 –
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Table 3 | Effect sizes, means (and standard deviations) for cognitive measures.
Measure d Int−Wait Time 1 Time 2 Time 3
T2/T3 Intervention
(n=15)
Waitlist
(n=13)
Community
(n=16)
Intervention
(n=15)
Waitlist
(n=13)
Community
(n=16)
Intervention
(n=15)
Waitlist
(n=12)
Neuropsychological battery (RBANS)
Total scale 0.19/ 0.32 97.2 (10.2) 94.5 (13.2) 98.3 (12.8) 106.4 (9.6)*** 101.5 (13.7)** 94.6 (13.9) 110.5 (10.4)*** 104.0 (10.0)***
Immediate memory 0.40/−0.04 97.7 (11.6) 97.2 (14.4) 100.5 (16.6) 104.3 (14.9) 98.4 (17.7) 99.3 (18.5) 112.3 (17.1)** 112.2 (10.2)**
Visuospatial/constructional 0.11/ 0.79 88.3 (12.8) 89.3 (14.3) 101.9 (15.1) 97.1 (14.1)* 96.5 (17.1)† 91.4 (18.3)** 98.5 (12.3) 88.5 (12.6)
Language −0.16/ 0.13 102.5 (15.1) 97.3 (7.2) 94.8 (14.0) 108.6 (6.9)† 105.5 (11.2)* 102.3 (11.6)* 107.2 (10.1) 100.4 (8.1)
Attention/concentration −0.25/−0.18 106.6 (13.7) 101.0 (17.9) 98.9 (15.3) 109.9 (10.9) 108.3 (13.1)* 101.1 (17.1) 112.8 (8.9)† 110.2 (16.3)**
Delayed memory 0.49/ 0.06 96.9 (8.8) 96.3 (17.3) 98.9 (11.1) 104.8 (12.3)** 97.5 (13.0) 101.5 (14.8) 106.5 (7.8)*** 105.1 (12.9)**
Trail making test (TMT)
TMT A 0.40/ 0.58 32.9 (7.4) 34.7 (12.9) 30.5 (8.8) 24.1 (5.2)** 30.2 (10.4) 26.5 (7.7) 23.2 (5.1)*** 31.2 (9.4)
TMT B −0.06/ 0.14 54.9 (11.7) 63.9 (24.1) 67.5 (22.1) 52.3 (13.2) 60.2 (24.2) 63.3 (20.6) 48.7 (14.8) 60.3 (24.9)
Self report (FACT-Cog 3)
Perceived cognitive impairments 0.67/ 0.31 33.7 (15.5) 34.4 (16.1) 75.4 (5.3) 45.6 (15.5)*** 35.4 (17.0) 73.4 (8.5) 50.2 (15.2)*** 46.0 (17.0)*
Comments from others 0.26/−0.20 12.7 (1.8) 12.0 (3.8) 15.4 (0.9) 14.5 (1.9)** 13.1 (2.2)† 15.8 (0.6) 13.9 (12.1) 13.8 (3.4)†
Perceived cognitive ability 0.65/ 0.68 13.5 (6.1) 16.2 (6.4) 32.1 (3.9) 17.5 (6.8)** 16.3 (6.6) 30.8 (6.8) 18.6 (8.1)* 16.9 (8.7)
Impact on QoL 0.13/ 0.22 8.8 (3.6) 9.3 (3.2) 15.6 (0.9) 10.3 (4.8)* 10.3 (3.3) 15.2 (1.8) 12.3 (4.6)*** 12.0 (2.3)**
Self report (BAPM)
Instrumental activities −0.15/ 0.56 19.5 (4.5) 22.2 (8.5) 18.8 (7.2) 20.5 (9.6) 17.9 (7.9) 16.8 (6.4)†
Basic activities 0.13/ 0.06 11.9 (4.1) 12.2 (4.3) – 12.4 (9.5) 13.3 (7.9) – 10.7 (4.2) 10.8 (3.4)
†p<0.10, *p<0.05, **p<0.01, ***p<0.001 for within-group comparison to Time 1.
Higher scores indicate better performance for RBANS and FACT-Cog 3. Lower scores indicate better performance forTrail Making and BAPM. dInt−Wait =effect size for Intervention improvement corrected for Waitlist
improvement. Effect sizes associated with statistically significant interactions for RCT participants (p<0.05) are shown in bold text; effect sizes associated with interaction trends (p< 0.10) are underlined.
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F (2, 50)= 5.88, p= 0.005, η2p = 0.19. The interaction occurred
because the two groups did not differ significantly in TMT
A completion times at Time 1, F (1, 25)= 0.08, p= 0.785,
η2p = 0.00 whereas the intervention group was significantly
faster than the control group at both Time 2, F (1, 25)= 4.77,
p= 0.038, η2p = 0.16, and Time 3, F (1, 25)= 7.98, p= 0.009,
η2p = 0.24. No other objective cognitive measure showed a
Group×Time interaction when analyzed for the two cancer
groups only.
For ANOVAs that included cancer and community groups from
Time 1 to Time 2, there were no main effects of group on objec-
tive cognitive function. There was a main effect of time on several
variables, in each case indicating significant improvements over
time. These time effects occurred for the RBANS Total score, F (1,
41)= 14.55, p< 0.001, η2p = 0.26, RBANS Language Index, F (1,
41)= 10.97, p= 0.002, η2p = 0.21, and TMT A, F (1, 41)= 11.50,
p= 0.002, η2p = 0.22. RBANS Total also showed a Group×Time
interaction, F (2, 41)= 5.34, p= 0.009, η2p = 0.21. The interac-
tion occurred because there were significant improvements on
RBANS Total from Time 1 to Time 2 for intervention, F (1,
41)= 16.10, p< 0.001, η2p = 0.28, and waitlist, F (1, 41)= 7.90,
p= 0.008, η2p = 0.16, but not community participants, F (1,
41)= 0.11, p= 0.737, η2p = 0.00. A Group×Time interaction for
the Visuospatial/Constructional index, F (2, 41)= 9.88, p< 0.001,
η2p = 0.33 occurred because the cancer groups scored significantly
worse than the community group at Time 1 (as noted above),
but there was no difference among the groups at Time 2, F (2,
41)= 0.54, p= 0.585,η2p = 0.03. Delayed Memory showed a trend
toward a Group×Time interaction, F (2, 41)= 3.02, p= 0.060,
η2p = 0.13. Simple effects testing showed that Delayed Memory
improved significantly from Time 1 to Time 2 for the intervention
group, F (1, 41)= 9.01, p= 0.005, η2p = 0.18, but not for waitlist,
p= 0.687, or community participants, p= 0.771. No other objec-
tive cognitive measure showed a Group×Time interaction when
analyzed across all three participant groups.
Clinical significance and reliable change scores were calculated
for changes from Time 1 to Time 2 and Time 1 to Time 3, respec-
tively, in order to more fully understand changes over time for
individuals in each of the groups. Fisher’s Exact Test showed sig-
nificant differences among the groups in the frequency of reliable
change categories for the RBANS visuospatial/constructional scale
at Time 2 (p= 0.030) and TMT A at Time 3 (p= 0.002). The
difference in category frequencies for Visuospatial/Constructional
scores at Time 3 approached statistical significance (p= 0.072).
Visuospatial/Constructional scores showed reliable improvement
or recovery at Time 2 for 27, 13, and 6% of intervention, wait-
list, and community participants, respectively, with an unexpected
reliable deterioration for 31% of community participants com-
pared with 0% of cancer survivor participants. By Time 3, 47%
of intervention and 8% of waitlist participants were classified as
recovered on the Visuospatial/Constructional score. For TMT A,
0% of intervention participants, 13% of waitlist participants and
6% of community participants showed reliable improvement or
recovery at Time 2. By Time 3, 46% of intervention and 0% of
waitlist participants showed recovery on TMT A.
Subjective cognitive function
Descriptive statistics and RCT effect sizes are shown in Table 3.
Both cancer groups reported significantly worse subjective cogni-
tive function than the community group at Time 1, on all four
FACT-Cog 3 subscales (all ps< 0.001).
For ANOVAs comparing the two cancer groups across three
time points, there were no main effects of group on subjective cog-
nitive function. There was a main effect of time on all FACT-Cog 3
measures, indicating significant improvements over time in these
subjective cognitive functions. For BAPM-instrumental activities,
a time effect approached significance, F (2, 50)= 3.14, p= 0.083,
η2p = 0.10. There was a trend toward a Group×Time interaction
for FACT-Cog perceived cognitive impairments, F (2, 50)= 3.14,
p= 0.052, η2p = 0.11. This trend was associated with significantly
reduced perceived impairments for the intervention group at Time
2, p= 0.002, and Time 3, p< 0.001, in comparison with the wait-
list group showing no change at Time 2, p= 0.999, but significant
improvement at Time 3, p= 0.013. There were no statistically sig-
nificant effects for the measures of subjective prospective memory
(BAPM), which were assessed in cancer survivor groups only.
For ANOVAs that included cancer and community groups
from Time 1 to Time 2, there were main effects of group on
all FACT-Cog 3 subscales, indicating worse subjective cognitive
function reported by the cancer survivor groups than the com-
munity comparison group. There were main effects of time for
perceived cognitive impairments, p= 0.025, and comments from
others, p= 0.001, and trends toward time effects for perceived
cognitive ability, p= 0.070, and impact on QoL, p= 0.083. In each
case, the time effects indicated better subjective cognitive function
over time. There was a Group×Time interaction for Perceived
Cognitive Impairments, F (2, 40)= 7.72, p= 0.001, η2p = 0.28.
The interaction occurred because the intervention group reported
significant improvement on Perceived Cognitive Impairment at
Time 2, F (1, 40)= 20.39, p< 0.001, η2p = 0.34, whereas the
other groups did not change significantly (waitlist p= 0.736, com-
munity p= 0.448). Impact on QoL showed a trend toward a
Group×Time interaction, F (2, 40)= 2.47, p= 0.097, η2p = 0.11.
Simple effects testing showed that Impact on QoL improved sig-
nificantly from Time 1 to Time 2 for the intervention group, F (1,
40)= 5.25, p= 0.027, η2p = 0.12, but not for waitlist, p= 0.170,
or community participants, p= 0.484. No other subjective cogni-
tive measure showed a Group×Time interaction when analyzed
across all three participant groups.
Changes for individuals according to clinical significance and
reliable change criteria showed a significant difference among
groups in categories of change from Time 1 to Time 2 in perceived
cognitive impairments, p= 0.002. There was clinically significant
improvement or recovery on perceived cognitive impairments by
Time 2 for 60, 17, and 0% of intervention, waitlist, and community
participants respectively. By Time 3, perceived cognitive impair-
ments showed clinically significant improvement or recovery for
73% of intervention and 50% of waitlist participants. A difference
among groups also occurred in change categories for comments
from others for Time 1 to Time 2, p= 0.047. There was clinically
significant improvement or recovery on this measure for 27% of
intervention, 18% of waitlist, and 0% of community participants
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at Time 2. At Time 3, clinically significant improvement or recov-
ery in comments from others was seen in 13% of intervention and
27% of waitlist participants, respectively. There were trends toward
differences in change categories for the BAPM-instrumental mea-
sure at Time 2, p= 0.075, and Time 3, p= 0.075. These effects for
the instrumental measure were associated with reliable change in
waitlist participants only and were the same at both time points:
one waitlist participant recovered (8 cf. 0% for intervention group)
and two other waitlist participants who were classified as “false
positive” (17 cf. 0% for intervention group).
PSYCHOSOCIAL RESULTS
Descriptive statistics and RCT effect sizes are shown in Table 4.
There were significant group effects at Time 1 for distress
(p< 0.001), QoL (p< 0.001 to p= 0.021), and fatigue (p= 0.005).
For distress, emotional function, cognitive function, and social
function, both cancer groups reported significantly worse function
at Time 1 than the community group. For physical function, role
function, global QoL, and fatigue, the intervention group reported
significantly worse Time 1 function than the community group
and the waitlist group did not differ significantly from the other
two groups.
For ANOVAs comparing the two cancer groups across three
time points, there were no main effects of group on psychoso-
cial measures. Seven of the 11 psychosocial measures showed time
main effects, indicating statistically significant improvements over
time in physical function, emotional function, subjective cognitive
function, social function, global QoL, CSE, and illness percep-
tions. The time main effect approached significance for fatigue,
F (2, 50)= 3.16, p= 0.051, η2p = 0.11, and K10 distress, F (2,
46)= 2.90, p= 0.065, η2p = 0.11. There was no effect of time for
either role function or benefit finding. There was a trend toward
a Group×Time interaction for social function, F (2, 50)= 2.52,
p= 0.091, η2p = 0.09. This trend was associated with statistically
significant improvement in social function over time for the inter-
vention group, F (2, 24)= 10.87, p< 0.001,η2p = 0.48, but not the
waitlist group, F (2, 24)= 1.92, p= 0.168, η2p = 0.14. There were
no other interactions for the two cancer survivor groups on the
psychosocial measures.
For ANOVAs that included cancer and community groups
from Time 1 to Time 2, there were main effects of group on all
psychosocial measures except for illness perceptions. These main
effects indicated worse QoL and more distress for cancer survivors
than for the community group. There were also main effects of
time, indicating significant improvement on physical function,
role function, emotional function, global QoL, fatigue, distress,
and illness perceptions. Social function showed a trend toward a
time effect, F (1, 40)= 3.69, p= 0.062, η2p = 0.08, leaving subjec-
tive cognitive function as the only psychosocial measure that did
not have a time main effect across the three groups. There was
a Group×Time interaction for social function, F (2, 40)= 4.54,
p= 0.017, η2p = 0.19. The interaction occurred because the inter-
vention group improved significantly in social function, F (1,
40)= 12.74, p= 0.001, η2p = 0.24, but there was no change for
the waitlist, F (1, 40)= 0.06, p= 0.804, η2p = 0.00, or community
groups, F (1, 40)= 0.19, p= 0.668, η2p = 0.01. Ta
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There was a trend toward a Group×Time interaction for dis-
tress, F (2, 39)= 2.46, p= 0.099, η2p = 0.11. This trend was
associated with a significant reduction in distress from Time 1 to
Time 2 for the intervention group, F (1, 39)= 10.69, p= 0.002,
η2p = 0.22, but no change for the waitlist, F (1, 39)= 0.68,
p= 0.414, η2p = 0.02, or community groups, F (1, 39)= 0.15,
p= 0.698, η2p = 0.00. There was no indication of interaction
effects on other psychosocial measures when analyzed across all
three participant groups.
Changes for individuals according to clinical significance and
reliable change criteria showed a trend toward a difference among
groups in categories of change from Time 1 to Time 3 in K10
distress, p= 0.059. From Time 1 to Time 2, one waitlist partici-
pant showed reliable improvement in distress (8%) compared to
0% of intervention and community participants. From Time 1 to
Time 3, there was clinically reliable recovery (five participants) or
improvement (two participants) in distress for intervention par-
ticipants (50% of intervention participants), compared to zero
waitlist participants recovered and three improved (25%). How-
ever, there was also clinically reliable worsening of distress by Time
3 for two intervention participants (14%) and one waitlist partici-
pant (8%). No other psychosocial measures approached statistical
significance for differences among participant groups in categories
of change for individuals.
ASSOCIATIONS BETWEEN COGNITIVE MEASURES AND POTENTIAL
PSYCHOSOCIAL MECHANISMS
In order to investigate the relationships between cognitive func-
tioning and potential mechanisms of change, a number of corre-
lations were calculated within the cancer survivor groups. Change
scores from Time 1 to Time 2 were calculated for illness perceptions
and CSE. These two sets of change scores were then investigated for
correlations with group (intervention or waitlist) and with Time
1 to Time 3 change scores for objective and subjective cognitive
measures (see Table 5).
As Table 5 shows, there was a statistically significant correlation
between improved CSE at Time 2 and improved FACT-Cog Impact
on QoL between Time 1 and Time 3. There was a similar trend
for CSE and FACT-Cog Perceived cognitive abilities, as well as
trends toward correlations between improved illness perceptions
and later improvements in FACT-Cog comments from others and
perceived cognitive abilities. Correlations between the CSE and
illness perceptions change scores with group assignment were not
statistically significant, but were in the predicted directions (as
were 17 of the 20 correlations in Table 5). The correlation between
CSE change and illness perceptions change was not statistically
significant, r (26)= –0.23, p= 0.269.
DISCUSSION
The current study used an RCT design to investigate the impact of
a group intervention program targeting cancer-related cognitive
dysfunction. Participants were cancer survivors who were ran-
domly allocated to the intervention or waitlist, as well as a sample
of people from the general public who participated as an addi-
tional non-randomized control group. The design incorporated
evaluation of two potential psychological mechanisms of change,
illness perceptions, and CSE.
Table 5 | Correlations between change in psychosocial predictors at
Time 2 and change in cognitive measures atTime 3.
Variable CSET2–T1 BIPQT2–T1
r (p) r (p)
Groupa 0.19 (0.349) −0.29 (0.156)
Objective change scores Time 3 – Time 1
RBANS (Total) 0.22 (0.279) −0.06 (0.777)
TMT A 0.17 (0.411) 0.24 (0.248)
TMT B −0.14 (0.480) −0.10 (0.627)
Subjective change scores Time 3 – Time 1
FACT-Cog 3
Perceived cognitive impairments 0.30 (0.129) −0.21 (0.301)
Comments from others −0.11 (0.605) −0.35 (0.086)
Perceived cognitive abilities 0.36 (0.068) −0.36 (0.068)
Impact on QoL 0.45 (0.020) −0.27 (0.188)
BAPM
IADL −0.01 (0.981) 0.02 (0.937)
BADL −0.06 (0.785) 0.20 (0.321)
aWaitlist=0, Intervention=1.
Higher scores indicate better performance for RBANS, FACT-Cog 3, and
CSE. Lower scores indicate better performance for TMT, BAPM, and Illness
Perceptions.
Outcome measures that showed significantly larger effect sizes
for intervention than waitlist participants were TMT A, perceived
cognitive impairments from FACT-Cog 3, and CSE. Additional
noteworthy trends indicating possible effects of the interven-
tion occurred for perceived cognitive ability from FACT-Cog 3,
social functioning, and fatigue. There were some indications of
improved CSE and illness perceptions being associated with later
improvements in subjective cognitive functioning.
OBJECTIVE COGNITIVE FUNCTION
There was partial support for Hypothesis 1, which predicted that
participating in the intervention may lead to improvements in
objective cognition. Intervention participants improved signifi-
cantly more than waitlist participants in the time taken to complete
TMT A. These results were consistent with the previous study
assessing ReCog (75), and another study assessing the MAAT pro-
gram (82), which also found significantly greater improvement
for the intervention group on this measure as well as contin-
ued improvement from Time 2 to Time 3. These findings suggest
ReCog to be beneficial for cognitive processes required in TMT
part A, such as processing speed, visual scanning, and numeric
sequencing. The current findings, in combination with results
of previous research, also suggest that participants may continue
to improve on some measures over a longer rather than shorter
follow-up period after the intervention. This may be due to the
practice-based nature of strategies included in ReCog and there-
fore further development of skills measured by these assessments
over time. These findings are relevant in the context of liter-
ature indicating attention and concentration, processing speed,
and executive functioning to be domains particularly vulnera-
ble to problems following cancer treatment (113). For all other
objective cognitive measures, there were main effects of time (or
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near-significant trends) for RCT participants, showing improve-
ment over time for cancer survivors but no Group×Time inter-
actions in ANOVA. Two previous RCTs have also found objective
benefits for a cognitive rehabilitation intervention compared to
waitlist to be limited to a single measure in the battery (86, 87).
Cancer survivors and community participants had equivalent
objective cognitive performance at baseline except for the RBANS
visuospatial/constructional index, which was significantly worse
for cancer survivors. This finding was congruent with previous
research indicating that visuospatial and verbal domains may
be areas mostly affected by cancer and cancer treatments (12).
Analyses of the community and cancer survivor data showed
statistically significant interactions for RBANS total and visu-
ospatial/constructional indices and a trend toward an interac-
tion for delayed memory. These interactions were associated
with bigger improvements for cancer survivors than for com-
munity participants, but with no difference in improvements
between intervention and waitlist participants. The RBANS find-
ings contrasted with a previous study of the same intervention,
which found significant improvement on the RBANS total score
for those who completed ReCog with a larger between-groups
effect size when compared to the cancer comparison group than
found in the current study (d = 1.00 vs. 0.19) (75). Research
has suggested that effect sizes reported in pilot studies often
differ from consequent RCT studies implementing the same
interventions (114).
It is possible that both the intervention and waitlist groups
showed improvement on RBANS measures due to practice effects
or increased effort at re-testing. For the community group,
although they may have also been motivated to participate due to
awareness they were assisting with cancer survivorship research,
they may not have been as motivated as the other two groups to
do well or to improve their performance. Another interpretation
of these findings could be that cancer survivors were less able to
demonstrate their cognitive abilities at initial assessment and thus
showed more benefit from repeat assessments than community
participants, but the lack of objective cognitive baseline differ-
ences between cancer survivors and community participants on
all but one measure makes this interpretation less likely. A further
possibility is that participating in the assessments (with or without
the intervention, and in the absence of feedback) helped give can-
cer survivors a sense that their cognitive performance was not as
bad as they had initially thought, improving CSE, which may have
helped them to improve their performance. This interpretation
is consistent with improvements over time for both interven-
tion and waitlist participants on subjective cognition and other
psychosocial measures.
Looking at changes for individuals in relation to reliable change
and clinical significance criteria, there were significant differences
between groups in categories of change, with more intervention
than waitlist participants showing “recovery” at Time 3 (TMT A
46 vs. 0% recovered; visuospatial/constructional index 47 vs. 8%
recovered). These results were promising and indicated greater
clinical improvement for participants who completed ReCog.
Unexpectedly, 31% of community participants showed reliable
“deterioration” on the visuospatial/constructional index at Time 2
(as also reflected in a significant simple effect of time within the
community group), which suggests that results on this measure
should be interpreted with caution.
SUBJECTIVE COGNITIVE FUNCTION AND OTHER PSYCHOSOCIAL
MEASURES
There was partial support for Hypothesis 2 regarding interven-
tion effects on subjective cognition. Intervention participants
improved significantly more than waitlist participants on FACT-
Cog perceived cognitive impairments from Time 1 to 2, but both
groups showed similar improvements from Time 1 to Time 3.
By Time 3, 73% of intervention and 50% of waitlist participants
showed clinically significant improvement or recovery on per-
ceived cognitive impairments. Perceived cognitive ability showed a
trend toward greater improvements for intervention than waitlist
participants. Other FACT-Cog subscales tended to improve over
time for both RCT groups. Again the improvements in the wait-
list group may indicate improved awareness, and an improvement
in perceptions, of cognitive functioning as a result of the testing
sessions. The variable length of time since participants had com-
pleted cancer treatments (see Table 2) argues against improvement
in the waitlist group being attributed solely to ongoing recovery.
Measures of prospective memory showed no statistically signifi-
cant effects, which differed from another intervention study in this
area that demonstrated improvement on this construct (104), but
a different measure was used in the current study.
Hypothesis 3, which proposed intervention effects on psy-
chosocial variables, was partially supported in relation to the
intervention group demonstrating trends toward greater improve-
ment in social functioning and fatigue, as shown by effect size
comparisons in Table 4. The social function trend replicated a
finding from the previous study of ReCog, but in both studies
the interpretation of this finding is tempered by the considera-
tion that the intervention group tended to report poorer social
function at baseline (75). The social support element of group
therapy and inclusion of broad elements in ReCog including self-
care issues such as fatigue management mean that these effects
could plausibly be associated with the intervention.
In contrast to objective measures, all four subjective cogni-
tive measures showed worse performance of the cancer survivors
than community participants at baseline. Cancer survivors also
reported significantly worse QoL, fatigue, and distress than com-
munity participants at baseline. These results were consistent with
previous literature suggesting an impact of cancer and cancer-
related treatments on these psychosocial areas of functioning, as
well as the finding that discrepancies between cancer survivors
and community participants are often greater on subjective than
objective measures of cognitive function (9). Although many of
the subjective cognitive and psychosocial measures improved over
time for the cancer survivors in the study, they continued to report
worse average functioning than demographically matched com-
munity participants on most self-report measures, as can be seen
from descriptive statistics in Tables 3 and 4. It would be of interest
to find out whether a longer intervention, individual treatment,
or more focus on broader issues would result in a higher pro-
portion of cancer survivors finishing an intervention or follow-up
period in the same range on subjective cognition and psychosocial
measures as people who have not experienced cancer.
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POTENTIAL MECHANISMS
There was partial support for Hypotheses 4 (regarding interven-
tion effects on illness perceptions and CSE) and 5 (regarding
changes in illness perceptions and CSE predicting other interven-
tion effects). CSE showed a significantly greater effect size for the
intervention than waitlist group, and simple effects of time within
group showed that both illness perceptions and CSE improved
significantly in the intervention but not the waitlist group. If an
intervention such as ReCog can deliver benefits by activating or
strengthening participants’ beliefs that they are capable of improv-
ing cognitive performance by means they can control (such as
use of skills practice or compensatory strategies), this would be
expected to be reflected in improvements on variables such as ill-
ness perceptions and CSE and there was some evidence for this
in the findings. However, neither variable could be directly com-
pared with community data at baseline, because the measures were
linked to perceptions of existing cognitive problems. To provide
some basis of comparison, community participants reported ill-
ness perceptions in relation to a hypothetical scenario: what they
thought it would be like if they experienced cognitive difficulties.
Cancer survivors, in contrast, reported illness perceptions in rela-
tion to the cognitive problems that they actually experienced (as
an inclusion criterion for the study). The illness perceptions that
cancer survivors reported were no worse than what community
participants imagined these problems would be like.
The occurrence of several statistically significant or near-
significant correlations between earlier change scores for CSE or
illness perceptions and later change scores for subjective cogni-
tive FACT-Cog-3 subscales gave some support for these variables
as potential mediators of intervention effect. The importance of
mindset to self-reported cognitive problems in cancer survivors
has previously been demonstrated via effects such as priming
(115). However, these correlations could also indicate the reverse
direction of causality or a third, common cause of change in
both sets of variables. Larger studies are needed for more rigorous
investigation of potential mediators of effect.
STRENGTHS AND LIMITATIONS
The study had a number of strengths. Groups were well matched
and included a non-cancer group for further understanding of
change over time as well as providing data for computing reli-
able change and clinical significance. Retention of participants
was high across all groups. Assessors were unaware of group allo-
cation for RCT participants serving to minimize observer bias.
The study used a previously reported, manualized intervention
and included assessment of potential mechanisms of intervention
effect. The study was also the first to include an adapted version
of the Traumatic Brain Injury Self-Efficacy Scale to assess CSE in
cancer survivors.
A limitation of the current study is that the community group
did not complete all of the measures administered to the treatment
and waitlist group, and community participants did not complete
a third assessment point. These issues occurred due to the com-
munity data being collected prior to the final selection of RCT
measures, and this has limited comparison of certain measures
and follow-up effects to the cancer groups only. The sample size in
the current study was also relatively small, which is similar to most
previous studies in this area, and impacts the power of analyses to
detect smaller effects that may nevertheless be of clinical signif-
icance. The risk of Type 1 error was adjusted within analyses of
each variable (e.g., use of simple effects analysis with a pooled error
term and Bonferroni correction) but not between variables. For
studies of this kind with larger sample sizes, it may also be benefi-
cial to consider stratification by types of cancer and/or treatment
during the randomization stage since these factors may influ-
ence the results. Results for the visuospatial/constructional index
should be interpreted with caution, because the community par-
ticipants unexpectedly performed significantly worse on this index
at retest, suggesting variability in performance on this index may
have been affected by factors other than practice and intervention
effects. One possibility is that community participants may have
felt less motivated to perform at their best at retest, but an RBANS
“effort index” comprised of tests independent of the visuospa-
tial/constructional scale (116) did not detect diminished effort
among community participants with significantly worse visuospa-
tial/constructional performance at retest. The need for subjective
scoring of one of the subtests in the measure also does not fully
account for the decrease, because it was also seen in performance
on an objectively scored subtest in the same index. Another con-
sideration in future studies could be to assess the use of hormonal
replacement therapy in community participants, since this may
impact outcomes. A final limitation of the current study was the
use of a waitlist rather than an active control group,which increases
the possibility of other factors contributing to the results and lim-
its the ability to attribute changes to the intervention. The use
of an active control group, and providing participants who are
not immediately engaged in an intervention with some form of
activity in the meantime, may control for issues associated with
potential expectation of benefit, time of testing, and attention. This
methodological improvement would provide a stronger research
design and allow interpretation of effects as being more clearly
attributable to the intervention.
FUTURE DIRECTIONS
Overall, these findings have provided further insight into the utility
of a psychological intervention for people experiencing cognitive
dysfunction following treatment for cancer. There was evidence to
support improvements in areas of subjective and objective cogni-
tive function, as well as areas of psychosocial functioning, for those
who completed the ReCog program. As the study was limited by
small sample size, it is difficult to generalize the results to the
broader population of people who experience cancer-related cog-
nitive dysfunction. However, the improvements observed in the
intervention group warrant further investigation of interventions
such as ReCog. Formal assessment of economic costs and benefits
would be helpful; the main costs associated with the intervention
are staff time and other resources required are few, although the
use of more costly or extensive assessments would increase the
resource requirements.
All intervention studies reported in this paper have found some
degree of improvement in objective and/or subjective cognitive
performance for post-treatment cancer survivors who are retested
over time. However, improvements also frequently occur in partic-
ipants who are waitlisted or who take part in interventions that are
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not specifically targeted toward cognitive rehabilitation. It will be
important for future research to more clearly define active ingre-
dients of interventions and to consider alternative approaches of
assisting cancer survivors with this issue. Careful selection of com-
parison conditions and studies with larger number of participants
will be important in this endeavor.
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